Jun 15, 2016 7:00am EDT Can-Fite Reports New Data Showing its Psoriasis Drug May Offer Efficacy Similar to Industry Leading Biologics Without Harmful Side Effects
Jun 07, 2016 7:00am EDT Can-Fite Submits Psoriasis Phase III Protocol and Registration Plan to EMA for Piclidenoson (CF101)
Jun 03, 2016 1:50pm EDT Can-Fite to Exhibit at Bio International Convention in San Francisco on June 6-9, 2016
Jun 01, 2016 7:00am EDT Can-Fite Reaches Agreement with EMA on Pivotal Phase III Clinical Trial with Piclidenoson (CF101) in Rheumatoid Arthritis
May 27, 2016 7:00am EDT Can-Fite Reports First Quarter 2016 Financial Results & Provides Clinical Pipeline Update
May 02, 2016 7:00am EDT Can-Fite to Present Data on CF602 in the Treatment of Erectile Dysfunction at American Urology Association's Annual Meeting
Apr 29, 2016 7:00am EDT Can-Fite to Present at Joseph Gunnar & Co.'s Pioneers 2016 Conference in New York City on May 5, 2016
Apr 11, 2016 7:00am EDT Can-Fite Announces New Pre-Clinical Data for CF602 Demonstrating Statistically Significant Full Recovery from Erectile Dysfunction After a Single Dose
Apr 04, 2016 7:00am EDT Can-Fite to Participate in BIO-Europe Partnering Conference on April 4-6, 2016 in Stockholm, Sweden
